Type(s) of Cancer
Multiple Myeloma
Multiple Myeloma
Study Phase
Phase 3
Study Completion Date
November 2025
November 2025
NCT01863550Uploaded 04-28-2023
Access via NCI by Request
PDS UID: nci-data-519
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Files: NCT01863550-D1



Data DictionaryNCT01863550-D1-Data-Dictionary_1.pdf

DATANCT01863550-D1-Dataset_3.csv

OTHERREADME.pdf
Files: NCT01863550-D2



Data DictionaryNCT01863550-D2-Data-Dictionary_1.pdf

DATANCT01863550-D2-Dataset_2.csv

OTHERREADME.pdf
Files: NCT01863550-D3



Data DictionaryNCT01863550-D3-Data-Dictionary_1.pdf

DATANCT01863550-D3-Dataset_2.csv

OTHERREADME.pdf
Files: NCT01863550-D4



Data DictionaryNCT01863550-D4-Data-Dictionary_1.pdf

DATANCT01863550-D4-Dataset_1.csv

OTHERREADME.pdf
Files: NCT01863550-D5



Data DictionaryNCT01863550-D5-Data-Dictionary_1.pdf

DATANCT01863550-D5-Dataset_3.csv

OTHERREADME.pdf
Files: NCT01863550-D6



Data DictionaryNCT01863550-D6-Data-Dictionary_1.pdf

DATANCT01863550-D6-Dataset_2.csv

OTHERREADME.pdf
Files: NCT01863550-D7



Data DictionaryNCT01863550-D7-Data-Dictionary_1.pdf

DATANCT01863550-D7-Dataset_1.csv

OTHERREADME.pdf